Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer / 中西医结合学报
Journal of Integrative Medicine
;
(12): 184-6, 2003.
Article
in Chinese
| WPRIM
| ID: wpr-449956
ABSTRACT
OBJECTIVE:
To observe the clinical effect of cinobufacini injection in treating moderate and advanced primary liver cancer (PLC).METHODS:
One hundred patients with moderate and advanced PLC were randomly divided into cino-treated group (50 patients) and control group (50 patients). The quality of life, tumor size, some changes of laboratory tests, and survival time were observed.RESULTS:
The progressive rate of cino-treated group (18%) was lower than that of the control group (32%). The quality of life of the cino-treated group (80%) was better than that of the control group (72%), but without statistical significance. The survival rate of >12 months of the cino-treated group (30%) was higher than that of the control group (18%). The patients' liver function such as serum total bilirubin and ALT decreased obviously in the cino-treated group while increased a lot in the control group. The level of AFP increased after treatment with statistical significance in the control group while there was no statistical significance in the cino-treated group.CONCLUSION:
Cinobufacini injection can not only inhibit the proliferation of cancer, but also protect liver function, improve quality of life and prolong survival time.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of Integrative Medicine
Year:
2003
Type:
Article
Similar
MEDLINE
...
LILACS
LIS